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EDITORIAL
Affecting the decline of renal function in diabetes mellitus
Diabetic renal disease in humans often requires the optimistic findings were not predicted by earlier observa-
better part of two decades to develop the signs and symp- tions in humans [2]. However, more than a decade ago,
toms of advanced/clinical diabetic nephropathy with un- Nyberg et al suggested a benefit of improved glycemic
derlying extensive damage to the various segments of control at advanced stages of diabetic nephropathy [7].
the nephron, thereby causing albuminuria, rising blood The Danish group and their patients were not able to
pressure, and a progressive decline of glomerular filtra- uniformly achieve their own goals for blood pressure nor
tion [1]. In the past, this stage has usually been classified those promulgated by an expert committee [8]. Yet, when
as one of inexorable progression leading to renal failure, Hovind et al studied those patients who successfully
dialysis, transplantation, or death [2], with the patient reached lower blood pressure levels and thus reduced
more likely to die of macrovascular disease than renal albuminuria on their own, spontaneously or through
disease [3]. Considering the decades-long progression of treatment, the decline in GFR in a significant fraction
the cellular and biochemical changes in diabetic patients began to replicate the Danish group’s definition of 1
facing progressive diabetic nephropathy, only under care- mL/min annually lost by healthy subjects [4]. Of great
fully crafted circumstances can animal models and bio- interest, the benefits of active reduction in blood pressure
chemical experiments provide pathophysiologic insight, occurred in people whose glycemic control was essen-
and only in combination with comprehensive study of tially identical to that of the conventionally treated sub-
the disease processes in humans. In this issue of Kidney jects in the Diabetes Control and Complications Trial
International, Hovind et al, at the Steno Diabetes Centre (DCCT) with type 1 diabetes [9] or the United Kingdom
in Gentofte, Denmark, contribute relevant observations Prospective Diabetes Study (UKPDS) with type 2 diabe-
to these issues with a summary of their long-term moni- tes [10]. Thus, antihypertensive medications clearly can
toring of the advanced stages of diabetic nephropathy, benefit patients who cannot achieve glycemic control
combined with their careful observational assessment equivalent to that of the intensively treated groups in
of the efficacy of antihypertensive agents in altering its the DCCT or UKPDS, an important message from the
course [4]. Danish paper.
Achieving the best possible outcome for diabetic pa- What guidelines can the clinician assimilate from this
tients with clear evidence of renal disease remains an and other work? At even advanced stages of diabetic
elusive goal, even at the Steno where a highly trained renal disease, application of the best possible glycemic
and integrated team of health care givers interact with control and the most intensive management of blood
each patient. Hovind et al, by effecting remission (lower pressure for the patients may slow (and in some cases
albuminuria) or regression [a slower fall in glomerular possibly reverse) the progression of diabetic renal dis-
filtration rate (GFR)] in significant fractions of patients ease. One may further assume that it is easier to reach
with advanced renal disease, suggested that mechanisms goals for blood pressure into the desired range than to
underlying the progression of disease can be modified approach euglycemia. However, Hovind et al [4] fairly
with active intervention using agents or collections of state that they could not reach the blood pressure targets
agents that effectively reduce blood pressure [4]. In ef- of the Joint National Committee (JNC-6) [8] in a sub-
fect, it may be an antihypertensive counterpart to the stantial fraction of their subjects. Other complicating and
reports of pancreas transplantation showing that even challenging factors (for instance, diabetic neuropathy)
advanced lesions of diabetic glomerulopathy may be may have obviated uniform success in the control of
ameliorated, but only with normoglycemia effected for as blood pressure. For the research community and for
long as 10 years [5, 6]. Taken together, these observations pharmaceutical research and development efforts, the
suggest a resiliency of the cellular and biochemical message also becomes clear—provide even better strate-
changes of diabetic renal disease in humans, even at the gies and agents that allow patients optimally to achieve
clinically defined late stages. For the most part, these (or realistically to approach) the goals of normoglycemia
and normotension. Alternatively, additional compounds
affecting different pathways of disease (for example,Key words: Hypertension, progressive diabetic nephropathy, albumin-
uria, glycemic control. pharmaceuticals that change the course of advanced gly-
cation of proteins and other compounds) may be added 2001 by the International Society of Nephrology
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to slow the progression or even reverse the manifesta- sally met in all diabetic patients, the work of Hovind et
al [4] indicates that each patient who approaches thetions of diabetic nephropathy.
The greater question subsumes the impact of optimal goal of normotension reduces the likelihood of rapidly
advancing diabetic renal disease and subsequent renalmanagement of hypertension and how the success may
affect the course of disease and thereby gain a greater replacement therapy.
understanding of the underlying cellular and biochemical
Michael W. Steffesmechanisms causing diabetic renal disease. First, Parving
Minneapolis, Minnesota, USAet al [1], and now his colleagues (as exemplified by Hov-
ind et al [4]), demonstrated the efficacy of antihyperten- Correspondence to Michael W. Steffes, M.D., Ph.D., Department of
Laboratory Medicine and Pathology, Mayo Mail Code 609, 420 Dela-sive medications in slowing the progressive fall in GFR.
ware St. S.E., Minneapolis, MN 55455, USAOne can speculate that changes at the cellular level due E-mail: Michael.W.Steffes-1@tc.umn.edu
to diabetic nephropathy may be affected by this treat-
ment; however, there is little information assessing com- REFERENCES
bined functional and structural changes altered by anti-
1. Parving HH, Andersen AR, Smidt UM, Svendsen PA: Earlyhypertensive interventions at late stages in humans. aggressive antihypertensive treatment reduces rate of decline in
Thus, it is important to determine whether the clear kidney function in diabetic nephropathy. Lancet 1:1175–1179, 1983
2. Kusmann MJ, Goldstein HH, Gleason RE: The clinical courseprolongation in the fall in GFR coincides with altered
of diabetic nephropathy. JAMA 238:1861–1863, 1976biochemical markers or amelioration of morphometri- 3. Bjork-Johnson K, Andersen P, Deckert T: The effect of protein-
cally determined lesions, as shown with pancreas trans- uria on relative mortality in type 1 (insulin-dependent) diabetes
mellitus. Dibetologia 28:590–596, 1985plantation [5, 6]. A current report, while showing no
4. Hovind P, Rossing P, Tarnow L, et al: Remission and regressionapparent benefit from three years of antihypertensive in the nephropathy of type 1 diabetes when blood pressure is
treatment on renal structure in patients with type 1 dia- controlled aggressively. Kidney Int 60:277–283, 2001
5. Fioretto P, Mauer SM, Bilous RW, et al: Effects of pancreasbetes, directly addressed these issues [11]. As the authors
transplantation on glomerular structure in insulin-dependent dia-state, a longer period of observation may be necessary, betic patients with their own kidneys. Lancet 342:1193–1196, 1993
as was the case with pancreas transplantation [5, 6]. 6. Fioretto P, Steffes MW, Sutherland DER, et al: Reversal of
lesions of diabetic nephropathy after pancreas transplantation.Some may take a pragmatic view that the clear demon-
N Engl J Med 339:69–75, 1998
stration of functional improvement is sufficient. How- 7. Nyberg G, Blohme G, Norden G: Impact of metabolic control in
progression of clinical diabetic nephropathy. Diabetologia 30:82–ever, with little insight into changes occurring in the
86, 1987glomeruli, tubules, or interstitium of the kidney, clinical
8. Sixth Report of the Joint National Committee on Prevention, De-
research goals will remain imbedded in reducing blood tection, Evaluation, and Treatment of High Blood Pressure. Arch
Intern Med 157:2413–2446, 1997pressure only and the assumption that the disease will
9. The Diabetes Control and Complications Trial Researchlikely not progress. Rather, greater intertwined biochem-
Group: The effect of intensive treatment of diabetes on the devel-
ical, structural, and functional insight may provide a ra- opment and progression of long-term complications of insulin-
dependent diabetes mellitus. N Engl J Med 329:977–984, 1993tionale for more innovative agents to alter the course of
10. UK Prospective Study Group: Intensive blood group with sulpho-disease. Optimal glycemic control ultimately prevents nylureas or insulin compared with conventional treatment and risk
diabetic complications; however, that possibility remains of complications in patients with type 2 diabetes. Lancet 352:837–
853, 1998a challenging opportunity rather than clinical reality for
11. ESPRIT Study Group: Effect of 3 years of antihypertensive ther-most patients with diabetes mellitus. Although the goals apy on renal structure in type 1 diabetic patients with albuminuria.
of normoglycemia and normotension may not be univer- Diabetes 50:843–850, 2001
